Anika Therapeutics | ANIK - أصول متداولة





أصول متداولة تغيير تاريخ
Abbott USD 25.51B 488M 2026-03
Agenus USD 133.44M 514K 2025-12
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.17B 223.75M 2025-12
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Heron Therapeutics USD 238.07M 8.67M 2025-12
Insmed USD 1.79B 137.6M 2025-12
Integra LifeSciences USD 1.17B 12.47M 2026-03
Intrexon USD 23.72M 45.04M 2024-06
J&J USD 59.17B 3.55B 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
Ligand Pharmaceuticals USD 832.27M 78.35M 2025-12
MacroGenics USD 219.94M 12.15M 2025-12
Merit Medical Systems USD 1.1B 61.62M 2026-03
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.16B 789M 2026-03
Smith & Nephew USD 4.63B 169M 2025-12
Stryker USD 13.34B 1.42B 2026-03
Surmodics USD 75.99M 5.31M 2025-06
Veracyte USD 522.17M 33.8M 2026-03
Xencor USD 599.82M 81.38M 2025-12
Zimmer Biomet Holdings USD 4.96B 157.4M 2026-03